Key result
Lower baseline plasma levels of glutamine and ornithine, and higher baseline levels of fumarate, were significantly associated with the progression of cardiovascular autonomic neuropathy over 3 years in patients with type 1 diabetes.
Why the study?
Because glycemic control alone does not prevent complications, it was hypothesized that disrupted amino acid and TCA cycle metabolic pathways contribute to the development and progression of diabetic CAN.
Do perturbations in amino acid and TCA cycle metabolism correlate with the progression of cardiovascular autonomic neuropathy in patients with type 1 diabetes?
Observational (n=57)
No
Do perturbations in amino acid and TCA cycle metabolism correlate with the progression of cardiovascular autonomic neuropathy in patients with type 1 diabetes?
Answers are grounded in this paper and cite their sources.
Amino acid/TCA metabolites may mark CAN progression in T1D; leaves open causal role or therapeutic targeting.
While diabetes is characterized by hyperglycemia, nutrient metabolic pathways like amino acid and tricarboxylic acid (TCA) cycle are also profoundly perturbed. As glycemic control alone does not prevent complications, we hypothesized that these metabolic disruptions are responsible for the development and progression of diabetic cardiovascular autonomic neuropathy (CAN). We performed standardized cardiovascular autonomic reflex tests and targeted fasting plasma metabolomic analysis of amino acids and TCA cycle intermediates in subjects with type 1 diabetes and healthy control subjects followed for 3 years. Forty-seven participants with type 1 diabetes (60% female and mean ± SD age 35 ± 13 years, diabetes duration 13 ± 7 years, and HbA1c 7.9 ± 1.2%) had lower fumarate levels and higher threonine, serine, proline, asparagine, aspartic acid, phenylalanine, tyrosine, and histidine levels compared with 10 age-matched healthy control subjects. Higher baseline fumarate levels and lower baseline amino acid levels—asparagine and glutamine—correlate with CAN (lower baseline SD of normal R-R interval [SDNN]). Baseline glutamine and ornithine levels also associated with the progression of CAN (lower SDNN at 3 years) and change in SDNN, respectively, after adjustment for baseline HbA1c, blood glucose, BMI, cholesterol, urine microalbumin-to- creatinine ratio, estimated glomerular filtration rate, and years of diabetes. Therefore, significant changes in the anaplerotic flux into the TCA cycle could be the critical defect underlying CAN progression.
No takes yet. Share an insight, caveat, or question.
Mathew et al. (2019) conducted an observational in Type 1 Diabetes and Cardiovascular Autonomic Neuropathy (n=57). Baseline plasma metabolic intermediates (amino acids and TCA cycle metabolites) vs. Healthy controls and intra-cohort metabolite level variations was evaluated on Correlation between baseline glutamine levels and SDNN (measure of cardiovascular autonomic neuropathy) at 3-year follow-up (r = 0.60, p=0.005). Lower baseline plasma levels of glutamine and ornithine, and higher baseline levels of fumarate, were significantly associated with the progression of cardiovascular autonomic neuropathy over 3 years in patients with type 1 diabetes.
Synapse has enriched 10 related papers. Consider them for comparative context: